01—Abstract
Summary
Summary of the 10-Q filed February 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Becton Dickinson and Company (BDX) reported a 2.6% increase in revenue for the third quarter of fiscal year 2024, reaching $4.706 billion, compared to $4.586 billiona in the prior year.
This growth was driven by price increases and a favorable foreign currency translation, partially offset by a decrease in volume and the impact of selling off the Surgical Instrumentation platform. Net income saw a significant decrease to $281 millionb ($0.96 per diluted share) from $509 million ($1.70 per diluted share) in the comparable prior-year period. This decline is primarily attributed to specified items, including integration and restructuring costs, purchase accounting adjustments, and European regulatory initiative-related costs, which had a substantial negative impact on earnings per share.
The company's financial performance reflects ongoing strategic initiatives, including simplification and cost-saving measures, which contributed to integration and restructuring expenses. Despite the year-over-year decrease in net income, operating cash flow remained strong at $855 millionc.
BDX also continued to return capital to shareholders through dividends and significant share repurchases, totaling $500 milliond in accelerated share repurchase agreements during the quarter. The company's balance sheet shows a decrease in cash and equivalents to $1.180 billion, but the overall financial position remains robust with adequate liquidity and access to financing facilities.
02—Key points
Key Highlights
- Revenue increased by 2.6% to $4.706 billion, driven by pricing and favorable foreign currency translation, although volume decreased.
- Net income decreased significantly to $281 million from $509 million in the prior year, largely due to $499 million in after-tax specified items.
- Diluted Earnings Per Share (EPS) fell to $0.96 from $1.70 year-over-year, impacted by specified items and foreign currency translation.
- Operating cash flow was robust at $855 million for the quarter, indicating strong underlying business performance.
- The company repurchased $500 million of its common stock under accelerated share repurchase agreements.
- The Medical segment showed revenue growth driven by Medication Delivery Solutions and Pharmaceutical Systems, despite challenges in China.
- The Interventional segment demonstrated solid growth, particularly in Surgery and Urology & Critical Care, even after the divestiture of the Surgical Instrumentation platform.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, Becton Dickinson & Co kept $0.06.
- Revenue$4.71B100.0%
- Cost of revenue−$2.68B56.9%
- Gross profit$2.03B43.1%
- Operating costs−$1.59B33.7%
- Operating income$439.0M9.3%
- Interest, other & tax−$158.0M3.4%
- Net income$281.0M6.0%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed February 1, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $4.71B$4.59B | +2.6% |
| Cost of Revenue | $2.68B$2.45B | +9.2% |
| Gross Profit | $2.03B$2.13B | −5.0% |
| R&D Expenses | $290.00M$313.00M | −7.3% |
| SG&A Expenses | $1.21B$1.19B | +2.2% |
| Operating Expenses | $4.27B$4.00B | +6.6% |
| Operating Income | $439.00M$585.00M | −25.0% |
| Interest Expense | $111.00M$102.00M | +8.8% |
| Net Income | $281.00M$509.00M | −44.8% |
| EPS (Basic) | $0.97$1.71 | −43.3% |
| EPS (Diluted) | $0.96$1.70 | −43.5% |
| Shares Outstanding (Basic) | 290.11M283.89M | +2.2% |
| Shares Outstanding (Diluted) | 291.40M285.34M | +2.1% |
05—Questions
Frequently Asked Questions
What is the primary driver behind the significant decrease in net income compared to the prior year?
The primary driver for the significant decrease in net income was the impact of 'specified items.' These include integration and restructuring costs, purchase accounting adjustments, and European regulatory initiative-related costs, which together amounted to $499 million after tax and had a substantial negative effect on the company's profitability.
How did the company manage its cash flow during the quarter?
Becton Dickinson generated strong operating cash flow of $855 million. The company also actively managed its capital structure by repurchasing $500 million of its common stock through accelerated share repurchase agreements and paid $275 million in dividends to common shareholders.
What are the key trends impacting the company's results of operations?
Key trends include adverse market dynamics in China (Volume-Based Procurement programs), elevated labor costs, limited labor availability, and potential logistics capacity constraints. Additionally, the shift of healthcare delivery to non-acute settings and increased focus on chronic disease management place financial pressure on healthcare institutions, potentially impacting demand for BD's products.
What is the status of the company's legal proceedings, particularly regarding product liability?
BDX is involved in numerous legal proceedings, including significant product liability claims related to hernia repair devices, pelvic mesh, IVC filters, and implantable ports. The company has an accrual of approximately $1.8 billion for product liability claims as of December 31, 2023. A class action lawsuit related to Alaris infusion pumps is nearing settlement for $85 million, with preliminary court approval obtained.
06—Continue